| Description | Isotetrandrine is a small molecule inhibitor, on various aspects of LPS-induced inflammation in vitro and in vivo. It dose-dependently suppresses the severity of LPS-induced ALI by inactivation of MAPK and NF-κB, which may involve the inhibition of tissue oxidative injury and pulmonary inflammatory process. |
| In vitro | In vitro, RAW 264.7 cells were pretreated with different dose of Isotetrandrine 1 h before treatment with 1 mg/L of LPS. In vivo, to induce ALI, male BALB/c mice were injected intranasally with LPS and treated with Isotetrandrine (20 and 40 mg/kg) 1 h before LPS. In vitro, the cytokine levels of tumor necrosis factor-α±, interleukin (IL)-1β, and IL-6 in supernatant were reduced by Isotetrandrine. Meanwhile, in vivo, pulmonary inflammatory cell infiltration, myeloperoxidase activity, total cells, neutrophils, macrophages, along with the levels of tumor necrosis factor-α±, IL-1β, and IL-6 in bronchoalveolar lavage fluid were dose-dependently attenuated by Isotetrandrine. Furthermore, our data showed that Isotetrandrine significantly inhibited the activation of MAPK and NF-κB, which are induced by LPS in ALI model. |
| molecular weight | 622.75 |
| Molecular formula | C38H42N2O6 |
| CAS | 477-57-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Isotetrandrine protects against lipopolysaccharide-induced acute lung injury by suppression of mitogen-activated protein kinase and nuclear factor-kappa B.J Surg Res. 2014 Apr;187(2):596-604. |